Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2006

01-03-2006 | Letter to the Editor

Lymphoma presenting as chronic aortic dissection in Marfan syndrome

Authors: Elias Lachanas, Periklis Tomos, Marianthi Fotinou, Spiros Miyakis

Published in: Annals of Hematology | Issue 3/2006

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Ansell SM, Armitage J (2005) Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80:1087–1097PubMedCrossRef
2.
Corso A, Pagnucco G, Morra E, Bernasconi C (1993) The diagnosis of non-Hodgkin’s lymphoma in a patient with Marfan’s syndrome. Minerva Med 84:417–419PubMed
3.
Inman GJ, Allday MJ (2000) Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt’s lymphoma and Epstein–Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 81:1567–1578PubMed
4.
Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
5.
Milewicz DM, Dietz HC, Miller DC (2005) Treatment of aortic disease in patients with Marfan syndrome. Circulation 111:e150–157PubMedCrossRef
6.
Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C, Kajii T, Jondeau G, Ohta T, Kishino T, Furukawa Y, Nakamura Y, Niikawa N, Boileau C, Matsumoto N (2004) Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36:855–860PubMedCrossRef
7.
Shabb NS, Fahl M, Shabb B, Haswani P, Zaatari G (1998) Fine-needle aspiration of the mediastinum: a clinical, radiologic, cytologic, and histologic study of 42 cases. Diagn Cytopathol 19:428–436PubMedCrossRef
Metadata
Title
Lymphoma presenting as chronic aortic dissection in Marfan syndrome
Authors
Elias Lachanas
Periklis Tomos
Marianthi Fotinou
Spiros Miyakis
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 3/2006
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-0036-6

Other articles of this Issue 3/2006

Annals of Hematology 3/2006 Go to the issue

Letter to the Editor

Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome

Original article

Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients’ peripheral blood erythroid cell culture

Letter to the Editor

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

Letter to the Editor

Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease

Original Article

Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia

Letter to the Editor

Is splenectomy a contraindication for patients with myelodysplastic syndromes complicated by splenomegaly?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits